TechFinance The company pipeline includes two Phase 2 products: CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia, and CPX-1 (a liposomal formulation of irinotecan :floxuridine)for the treatment of colorectal ...
The Pharma Letter In February 2013, the European Commission granted marketing authorization in Europe for Zaltrap in combination with irinotecan /5-fluorouracil/folinic acid chemotherapy in adult with metastatic colorectal cancer that is resistant to or has progressed ... and more »
Healio Patients assigned to arm A (n=70) received cetuximab and chemotherapy (fluorouracil, leucovorin and irinotecan or modified fluorouracil, leucovorin and oxaliplatin). Patients assigned to arm B (n=68) received chemotherapy alone. The rate of conversion ...
FiercePharma In February 2013, the European Commission (EC) granted marketing authorization in the European Union for ZALTRAP concentrate for solution for infusion in combination with irinotecan /5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with ... and more »
Private Equity Hub (press release) ... (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. and more »
